Lumit™ Cytokine Immunoassays for Biologics
In biologics research, particularly with monoclonal antibodies and cell and gene therapy products, activating immune cells is a key action mechanism. Conducting potency assays to measure cytokine release from these cells is crucial for both lot release and characterization. While ELISAs have traditionally been used for cytokine detection, they can be cumbersome and time-consuming. Lumit™ Cytokine Immunoassays offer a more rapid solution with direct cytokine detection in the well alongside cultured cells. This method eliminates the need for wash steps, allowing you to obtain results in 70 minutes or less with comparable results to ELISA. Additionally, the assays’ extended dynamic range eliminates the need for sample dilutions.
- Lumit™ IL-2 (Human)
- Lumit™ IL-4 (Human)
- Lumit™ IL-6 (Human)
- Lumit™ IL-10 (Human)
- Lumit™ IFN-γ (Human)
- Lumit™ TNF-α (Human)
- Lumit™ IL-12 (Human)
- Lumit™ IL-1β Human/Mouse
- Lumit™ IL-17A (Human)
- Lumit™ IL-8 (Human)
- Lumit™ IFN-β (Human)
- Lumit™ HMGB1 Human/Mouse
- Lumit™ Active IL-18 (Human)
ADCC/ADCP reporter bioassays
Promega’s ADCC (Antibody-Dependent Cellular Cytotoxicity) and ADCP(Antibody-Dependent Cellular Phagocytosis) Reporter Bioassays are specifically designed to assess the effectiveness of antibodies and other biologics that target and activate Fcγ receptors. These assays utilize Jurkat cells, which are modified to stably express specific Fcγ receptor variants and a luciferase gene under the control of the NFAT response element. This design makes them biologically relevant and closely aligned with the actual mechanism of action (MOA) of the biologics being tested.
The advantage of these bioassays lies in their simplicity and scalability. They offer a more straightforward, reliable, and less labor-intensive alternative to traditional primary cell assays. This approach provides quantitative, low-variability, and highly accurate measurements of both ADCC and ADCP activities.
- ADCC Reporter Bioassay, V Variant
- ADCC Reporter Bioassay, F Variant
- Mouse FcγRIV ADCC Bioassay
- FcγRI ADCP Bioassay
- FcγRIIa-H ADCP Bioassay
- More ADCC/ADCP options
- Lumit™ FcγR Binding Immunoassays
TCRαβ-KO: T Cell Activation Bioassay for Transgenic TCRs
Traditional methods for measuring TCR activation are often cumbersome and produce inconsistent results. The TCRαβ-KO Bioassay addresses these challenges, providing a more efficient means of testing transgenic TCRs. This is crucial for determining antigen specificity, safety, and effectiveness, particularly in contexts such as quality control and in the development of TCR-T and CAR-T therapies.
The T Cell Activation Bioassay (TCRαβ-KO) utilizes a bioluminescent, cell-based technique to measure the potency of transgenic TCR constructs in activating T cells, independent of endogenous TCR expression. This assay employs a specially engineered Jurkat T cell line, where the native TCR α and β chains are knocked out using CRISPR/Cas9 technology. These modified cells also feature a luciferase reporter gene, which is activated via a TCR pathway-dependent promoter.
HiBiT Target Cell Killing Bioassay
The HiBiT Target Cell Killing (TCK) Bioassay platform is a cutting-edge tool designed for the precise and highly sensitive measurement of target cell destruction. This assay is particularly effective in assessing the impact of various biologic drugs, including monoclonal antibodies (mAbs), bispecific antibodies, and CAR-T cells. Notable for its simplicity and homogeneity, the assay generates a strong luminescent signal upon lysis of the target cells, detectable with a standard luminometer.